Dominance of multidrug resistant CC271 clones in macrolide-resistant streptococcus pneumoniae in Arizona

Jolene Bowers; Elizabeth Driebe; Jennifer Nibecker; Bette Wojack; Derek Sarovich; Ada Wong; Pius Brzoska; Nathaniel Hubert; Andrew Knadler; Lindsey Watson; David M Wagner; Manohar Furtado; Michael Saubolle; David M Engelthaler; Paul S Keim

doi:10.1186/1471-2180-12-12

Dominance of multidrug resistant CC271 clones in macrolide-resistant streptococcus pneumoniae in Arizona

Jolene Bowers, Elizabeth Driebe, Jennifer Nibecker, Bette Wojack, Derek Sarovich, Ada Wong, Pius Brzoska, Nathaniel Hubert, Andrew Knadler, Lindsey Watson, David M Wagner, Manohar Furtado, Michael Saubolle, David M Engelthaler, Paul S Keim

Research output: Contribution to journal › Article › peer-review

10 Downloads (Pure)

Abstract

Background: Rates of resistance to macrolide antibiotics in Streptococcus pneumoniae are rising around the world due to the spread of mobile genetic elements harboring mef(E) and erm(B) genes and post-vaccine clonal expansion of strains that carry them.

Results: Characterization of 592 clinical isolates collected in Arizona over a 10 year period shows 23.6% are macrolide resistant. The largest portion of the macrolide-resistant population, 52%, is dual mef(E)/erm(B)-positive. All dual-positive isolates are multidrug-resistant clonal lineages of Taiwan19F-14, mostly multilocus sequence type 320, carrying the recently described transposon Tn2010. The remainder of the macrolide resistant S. pneumoniae collection includes 31% mef(E)-positive, and 9% erm(B)-positive strains.

Conclusions: The dual-positive, multidrug-resistant S. pneumoniae clones have likely expanded by switching to non-vaccine serotypes after the heptavalent pneumococcal conjugate vaccine release, and their success limits therapy options. This upsurge could have a considerable clinical impact in Arizona.

Original language	English
Pages (from-to)	1-10
Number of pages	10
Journal	BMC Microbiology
Volume	12
DOIs	https://doi.org/10.1186/1471-2180-12-12
Publication status	Published - 2012

Access to Document

10.1186/1471-2180-12-12Licence: Other

5385162-oaFinal published version, 349 KBLicence: Other

Cite this

Bowers, J., Driebe, E., Nibecker, J., Wojack, B., Sarovich, D., Wong, A., Brzoska, P., Hubert, N., Knadler, A., Watson, L., Wagner, D. M., Furtado, M., Saubolle, M., Engelthaler, D. M., & Keim, P. S. (2012). Dominance of multidrug resistant CC271 clones in macrolide-resistant streptococcus pneumoniae in Arizona. BMC Microbiology, 12, 1-10. https://doi.org/10.1186/1471-2180-12-12

@article{1211a83e29e6440080f8115c53cbcb6a,

title = "Dominance of multidrug resistant CC271 clones in macrolide-resistant streptococcus pneumoniae in Arizona",

abstract = "Background: Rates of resistance to macrolide antibiotics in Streptococcus pneumoniae are rising around the world due to the spread of mobile genetic elements harboring mef(E) and erm(B) genes and post-vaccine clonal expansion of strains that carry them.Results: Characterization of 592 clinical isolates collected in Arizona over a 10 year period shows 23.6% are macrolide resistant. The largest portion of the macrolide-resistant population, 52%, is dual mef(E)/erm(B)-positive. All dual-positive isolates are multidrug-resistant clonal lineages of Taiwan19F-14, mostly multilocus sequence type 320, carrying the recently described transposon Tn2010. The remainder of the macrolide resistant S. pneumoniae collection includes 31% mef(E)-positive, and 9% erm(B)-positive strains.Conclusions: The dual-positive, multidrug-resistant S. pneumoniae clones have likely expanded by switching to non-vaccine serotypes after the heptavalent pneumococcal conjugate vaccine release, and their success limits therapy options. This upsurge could have a considerable clinical impact in Arizona.",

author = "Jolene Bowers and Elizabeth Driebe and Jennifer Nibecker and Bette Wojack and Derek Sarovich and Ada Wong and Pius Brzoska and Nathaniel Hubert and Andrew Knadler and Lindsey Watson and Wagner, {David M} and Manohar Furtado and Michael Saubolle and Engelthaler, {David M} and Keim, {Paul S}",

year = "2012",

doi = "10.1186/1471-2180-12-12",

language = "English",

volume = "12",

pages = "1--10",

journal = "BMC Microbiology",

issn = "1471-2180",

publisher = "Global Science Books",

}

TY - JOUR

T1 - Dominance of multidrug resistant CC271 clones in macrolide-resistant streptococcus pneumoniae in Arizona

AU - Bowers, Jolene

AU - Driebe, Elizabeth

AU - Nibecker, Jennifer

AU - Wojack, Bette

AU - Sarovich, Derek

AU - Wong, Ada

AU - Brzoska, Pius

AU - Hubert, Nathaniel

AU - Knadler, Andrew

AU - Watson, Lindsey

AU - Wagner, David M

AU - Furtado, Manohar

AU - Saubolle, Michael

AU - Engelthaler, David M

AU - Keim, Paul S

PY - 2012

Y1 - 2012

N2 - Background: Rates of resistance to macrolide antibiotics in Streptococcus pneumoniae are rising around the world due to the spread of mobile genetic elements harboring mef(E) and erm(B) genes and post-vaccine clonal expansion of strains that carry them.Results: Characterization of 592 clinical isolates collected in Arizona over a 10 year period shows 23.6% are macrolide resistant. The largest portion of the macrolide-resistant population, 52%, is dual mef(E)/erm(B)-positive. All dual-positive isolates are multidrug-resistant clonal lineages of Taiwan19F-14, mostly multilocus sequence type 320, carrying the recently described transposon Tn2010. The remainder of the macrolide resistant S. pneumoniae collection includes 31% mef(E)-positive, and 9% erm(B)-positive strains.Conclusions: The dual-positive, multidrug-resistant S. pneumoniae clones have likely expanded by switching to non-vaccine serotypes after the heptavalent pneumococcal conjugate vaccine release, and their success limits therapy options. This upsurge could have a considerable clinical impact in Arizona.

AB - Background: Rates of resistance to macrolide antibiotics in Streptococcus pneumoniae are rising around the world due to the spread of mobile genetic elements harboring mef(E) and erm(B) genes and post-vaccine clonal expansion of strains that carry them.Results: Characterization of 592 clinical isolates collected in Arizona over a 10 year period shows 23.6% are macrolide resistant. The largest portion of the macrolide-resistant population, 52%, is dual mef(E)/erm(B)-positive. All dual-positive isolates are multidrug-resistant clonal lineages of Taiwan19F-14, mostly multilocus sequence type 320, carrying the recently described transposon Tn2010. The remainder of the macrolide resistant S. pneumoniae collection includes 31% mef(E)-positive, and 9% erm(B)-positive strains.Conclusions: The dual-positive, multidrug-resistant S. pneumoniae clones have likely expanded by switching to non-vaccine serotypes after the heptavalent pneumococcal conjugate vaccine release, and their success limits therapy options. This upsurge could have a considerable clinical impact in Arizona.

U2 - 10.1186/1471-2180-12-12

DO - 10.1186/1471-2180-12-12

M3 - Article

VL - 12

SP - 1

EP - 10

JO - BMC Microbiology

JF - BMC Microbiology

SN - 1471-2180

ER -

Dominance of multidrug resistant CC271 clones in macrolide-resistant streptococcus pneumoniae in Arizona

Abstract

Access to Document

Fingerprint

Cite this